Axsome: New Major Depressive Disorder Trial Data

 Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months

Improvement in disability, measured by the SDS, starting at week 1 and sustained over 12 months

https://www.biospace.com/article/axsome-therapeutics-presents-new-data-from-the-evolve-open-label-trial-demonstrating-effects-of-auvelity-on-cognitive-and-physical-functioning-in-patients-with-major-depressive-disorder/